Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Prof Med J 30:764770
(PubMed) Cacciatore L, Cerio R, Ciarimboli M, et al
Nakamura S, Sugiyama S, Fujioka D, Kawabata K, Ogawa H, Kugiyama K
Chisum, H
Following the positive REDEFINE 1 Phase 3 data (published June 2025, PMID: 40544433), Novo Nordisk announced plans to file regulatory applications for CagriSema for obesity in the United States (FDA), European Union (EMA), and other major markets in 20252026
US$ 20.63
US$ 21.70
US$ 22.12
US$ 28.77
US$ 20.06
